Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 12/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.69 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 4/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1653671 | 1.00 | GCK (0.69) | GCKKCNH2LRRK2IRAK4GRM5 | |
| SCHEMBL13523843 | 0.96 | GCK (0.74) | GCKKCNH2LRRK2GRM5 | |
| SCHEMBL1380138 | 0.96 | GCK (0.76) | GCKKCNH2GRM5 | |
| SCHEMBL1377444 | 0.96 | GCK (0.74) | GCKKCNH2LRRK2GRM5 | |
| SCHEMBL1427331 | 0.93 | GCK (0.75) | GCKKCNH2LRRK2 | |
| SCHEMBL1377556 | 0.91 | GCK (0.62) | GCKKCNH2GRM5 | |
| SCHEMBL1427127 | 0.87 | GCK (0.63) | GCKKCNH2 | |
| SCHEMBL1380537 | 0.87 | GCK (0.63) | GCKKCNH2GRM5 | |
| SCHEMBL1427446 | 0.87 | GCK (0.65) | GCKKCNH2 | |
| SCHEMBL12782090 | 0.86 | GCK (0.53) | GCKKCNH2LRRK2LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977328-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-07-12 | — | — | US | claimed |
| EP-2305674-A1 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | claimed |
| US-20090111790-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | claimed |
| US-7977328-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-07-12 | — | — | US | disclosed |
| US-7977328-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-07-12 | — | — | US | disclosed |
| US-7977328-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-07-12 | — | — | US | disclosed |
| EP-2305674-A1 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| EP-2301929-A1 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | AstraZeneca AB (Publ) (SE) | 2011-03-30 | — | — | EP | disclosed |
| EP-2301935-A1 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | AstraZeneca AB (Publ) (SE) | 2011-03-30 | — | — | EP | disclosed |
| US-7842694-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2010-11-30 | — | — | US | disclosed |
| US-7842694-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2010-11-30 | — | — | US | disclosed |
| US-20090118159-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-20090118159-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-20090118159-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-20090111790-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111790-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111790-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090029905-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20090029905-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20090029905-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029905-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | GCK, GCKR, GK | GCK 1/4885KCNH2 1128/4885LRRK2 4282/4885 |
| US-20090111790-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | GCK, GCKR, GK | GCK 1/4885KCNH2 993/4885LRRK2 4034/4885 |
| US-20090118159-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | GCK, GCKR, GK | GCK 1/4885KCNH2 993/4885LRRK2 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.